Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12356867 | 0.92 | ALDH1A1 (0.85) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL14341837 | 0.83 | MEN1 (1.00) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL23676922 | 0.82 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL15537079 | 0.77 | MAPT (0.63) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL12017108 | 0.77 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL29757005 | 0.77 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL27436851 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL12406395 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL29254327 | 0.75 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL27928462 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2AL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-12 | — | — | US | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | FAAH, FAAH2, CNR2 | ALDH1A1 734/4885MEN1 3260/4885KMT2A 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.